Glenmark Pharmaceuticals is a global drug-maker that has spent the last decade transforming itself from a seller of generic copycat pills into a creator of branded, patent-protected medicines - a shift it calls “Glenmark 3.0”. Founded in 1977, the company now operates in over 80 countries, and the clearest proof of its new identity arrived in 2025 when its innovation engine, IGI, licensed a novel cancer drug to AbbVie for $700 million upfront. The recurring approach that explains everything else is a deliberate climb up the value chain: from simple generics to complex generics, then to branded specialty products, and finally to discovering its own innovative biologics, with over 60% of revenues already coming from branded markets.
Business segments
A single pharmaceutical engine with four distinct layers - a branded-generics foundation in India and emerging markets, a specialty push in the US and Europe, a pipeline of in-licensed oncology drugs, and a self-sustaining biologics innovation unit - all fed by the same global manufacturing and distribution backbone.
1. India branded formulations: the profit engine that funds the future
A top-15 domestic business built on chronic therapies and first-to-market launches, where 11 brands rank in the country’s top 300 and the company consistently grows faster than the market.
- Chronic therapies provide the base - 57% of India sales come from long-term treatments in cardiac, respiratory, and diabetes care, which means recurring prescriptions rather than one-off purchases.
- First-in-India launches create a lead - the company introduced the world’s first fixed-dose triple therapy for COPD in a single nebulizer, the first biosimilar of the GLP-1 drug Liraglutide, and a first-of-its-kind oral treatment for severe eczema, each time securing a window with no direct competition.
- A 2,100-strong sales force pushes into every corner - the business reaches doctors and pharmacies through a direct field force and a network of 4,000 distributors, which is how it holds the number-two spot in dermatology and number-three in respiratory.
- Consumer care is being carved out for sharper focus - the over-the-counter portfolio, including a powder brand with a 57% market share, was moved into a separate subsidiary on 14 August 2025 so the main business can concentrate on prescription drugs.
2. North America: the generics base turning specialty
The 15th-largest generic company in the US by prescriptions, now shifting from a pure generics model to directly commercializing its own branded specialty products.
- A 206-product generic shelf with a regulatory reset - the US portfolio spans oral solids, injectables, and respiratory drugs, and the Monroe, North Carolina factory received a clean “VAI” classification from the FDA in late 2025, allowing commercial manufacturing to restart after a period of remediation.
- RYALTRIS marks the move to branded selling - in April 2026, the company began selling its allergy nasal spray directly to US doctors and payers rather than through a partner, its first innovative product with a direct American commercial presence.
- Respiratory exclusivity windows are the near-term opportunity - a generic FloVent inhaler won Competitive Generic Therapy designation with 180 days of exclusivity, and three more respiratory applications were filed during the year.
- A legacy legal overhang is resolved - a drug-pricing case from the 2013-2015 period was settled through a three-year deferred prosecution agreement and a related civil settlement, clearing the path for the business to focus forward.
3. Europe: the branded dermatology and respiratory beachhead
The fastest-growing region, expanding at more than 25% annually over three years, anchored by a flagship allergy spray and a newly approved acne drug that is the company’s first novel chemical entity on the continent.
- RYALTRIS is the door-opener - the nasal spray has captured high double-digit market share in markets like Italy, Poland, and the Czech Republic, giving the sales force a reason to call on doctors and build relationships.
- WINLEVI is the step-up to innovative dermatology - European Commission approval in late 2025 for this first-in-class acne cream lets Glenmark launch a novel molecule across 15 EU countries, moving beyond branded generics into patent-protected territory.
- Legacy respiratory brands hold the fort in Central Europe - older products like SALMEX and ASTHMEX still command over 15% market share in some CEE markets, providing a steady income stream while the new launches ramp up.
- Growth comes through in-licensing, not just internal development - the business signed 21 in-licensing deals in a single year, using other companies’ molecules to fill its bag and expand geographically.
4. Emerging markets: the branded footprint across four continents
A branded-generics and specialty operation spanning Russia, Latin America, Africa, and Asia-Pacific, where the company is often a top-10 player in respiratory and dermatology and is now seeding an oncology pipeline.
- Local leadership positions create pricing power - Glenmark is the number-one pharma company in Kenya’s covered market, the second-largest Indian company in Russia, and a top-10 respiratory player in Brazil and Mexico, which means it negotiates from strength with hospitals and distributors.
- RYALTRIS is the leading allergy spray in most markets where it is sold - the product has been launched in 55 countries and is now entering China, Thailand, and soon Brazil, creating a global brand that travels across regions.
- An oncology pipeline is being built for the next wave - marketing applications for a subcutaneous PD-L1 inhibitor have been filed in 24 markets, and two more cancer drugs (a HER2 ADC and a third-generation EGFR inhibitor) are on track for filings and launches over the next two years.
- The model is science-led, not just sales-led - the business deploys Medical Affairs teams and Patient Access Programs alongside its commercial force, which is how it introduces complex biologics into markets with very different regulatory and payment systems.
5. Ichnos Glenmark Innovation: the biologics discovery engine
A clinical-stage biotech inside the group that designs multispecific antibodies for cancer and autoimmune diseases, made financially self-sustaining by a landmark deal with AbbVie.
- The BEAT platform is the crown jewel - this proprietary technology lets IGI build antibodies that hit two or three targets at once, and it was the foundation for the trispecific antibody that AbbVie licensed for $700 million upfront.
- The AbbVie deal changed the economics - beyond the upfront cash, the agreement includes up to $1.225 billion in milestones and tiered double-digit royalties, while Glenmark keeps the rights to sell the drug across emerging markets.
- A pipeline of next-generation assets is advancing - a multispecific immune-cell activator for solid tumors is headed toward an IND filing by end-2026, and two earlier-stage programs are in preclinical development, so the engine is not a one-asset bet.
- The model is now capital-light - IGI shut its own manufacturing plant in Switzerland and moved to a network of contract manufacturers, which means it can focus its 150 scientists across New York, Lausanne, and Mumbai entirely on discovery and clinical development.
Group structure and partners
A parent company in Mumbai with a web of subsidiaries and partnerships that separate the innovation engine, the consumer business, and the in-licensing vehicle from the core formulations operations.
- The group was deliberately split into three independent entities - formulations (Glenmark Pharmaceuticals), active pharmaceutical ingredients (Glenmark Life Sciences), and biologics innovation (Ichnos Sciences) were separated with their own management teams, and the API unit later divested a 75% stake to Nirma in 2024, with Glenmark retaining a 7.84% minority stake.
- A dedicated subsidiary handles every in-licensing deal - Glenmark Specialty S.A. is the legal vehicle through which the company licenses drugs like WINLEVI, envafolimab, and the two oncology assets from Hengrui and Hansoh, keeping those rights ring-fenced.
- Consumer care and nebulizers now live in their own subsidiaries - the consumer portfolio was moved to Glenmark Consumer Care Limited in 2025, and the nebulizer brands and intellectual property were transferred to Glenmark Healthcare Limited in 2026, each with its own strategic mandate.
- Key partners span the globe - AbbVie, Almirall, and Astria are the out-licensing partners for IGI’s biologics; Cosmo, Hengrui, Hansoh, Alphamab, BeiGene, and Pfizer are the in-licensing partners that supply molecules; and Menarini, Grand Pharmaceutical, Yuhan, and Organon are the regional commercialization partners for RYALTRIS.